Patient and disease characteristics and univariate analysis
| Variable . | Overall survival . | Failure-free survival . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients . | No. of deaths . | 5-y overall survival, % . | Wilcoxon P . | No. of patients . | No. of deaths . | 5-y failure-free survival, % . | Wilcoxon P . | |
| Age, y | < .001 | < .001 | ||||||
| Less than 45 | 109 | 13 | 90 ± 3 | 108 | 19 | 84 ± 4 | ||
| 45 or more | 36 | 18 | 62 ± 8 | 36 | 21 | 55 ± 8 | ||
| Sex | .24 | .40 | ||||||
| Male | 74 | 20 | 82 ± 5 | 73 | 23 | 73 ± 5 | ||
| Female | 71 | 11 | 85 ± 4 | 71 | 17 | 80 ± 5 | ||
| Stage | .04 | .11 | ||||||
| I, II | 83 | 13 | 88 ± 4 | 83 | 20 | 81 ± 4 | ||
| III, IV | 61 | 18 | 76 ± 6 | 60 | 20 | 69 ± 6 | ||
| IPS | .002 | .003 | ||||||
| 2 or below | 104 | 17 | 83 ± 3 | 103 | 24 | 82 ± 4 | ||
| More than 2 | 35 | 13 | 67 ± 8 | 35 | 15 | 60 ± 8 | ||
| Bulky disease | .65 | .79 | ||||||
| No | 101 | 24 | 81 ± 4 | 100 | 30 | 76 ± 4 | ||
| Yes | 37 | 7 | 86 ± 6 | 37 | 10 | 74 ± 8 | ||
| HGAL | .01 | .05 | ||||||
| Negative | 37 | 13 | 70 ± 8 | 37 | 15 | 70 ± 8 | ||
| Positive | 108 | 18 | 87 ± 3 | 107 | 25 | 79 ± 4 | ||
| B symptoms* | .48 | .14 | ||||||
| No | 73 | 12 | 87 ± 4 | 72 | 16 | 85 ± 4 | ||
| Yes | 46 | 10 | 84 ± 6 | 46 | 15 | 69 ± 7 | ||
| No. of sites* | .79 | .25 | ||||||
| 1-3 | 72 | 13 | 87 ± 4 | 72 | 17 | 83 ± 4 | ||
| More than 3 | 44 | 9 | 82 ± 6 | 43 | 13 | 72 ± 7 | ||
| Variable . | Overall survival . | Failure-free survival . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients . | No. of deaths . | 5-y overall survival, % . | Wilcoxon P . | No. of patients . | No. of deaths . | 5-y failure-free survival, % . | Wilcoxon P . | |
| Age, y | < .001 | < .001 | ||||||
| Less than 45 | 109 | 13 | 90 ± 3 | 108 | 19 | 84 ± 4 | ||
| 45 or more | 36 | 18 | 62 ± 8 | 36 | 21 | 55 ± 8 | ||
| Sex | .24 | .40 | ||||||
| Male | 74 | 20 | 82 ± 5 | 73 | 23 | 73 ± 5 | ||
| Female | 71 | 11 | 85 ± 4 | 71 | 17 | 80 ± 5 | ||
| Stage | .04 | .11 | ||||||
| I, II | 83 | 13 | 88 ± 4 | 83 | 20 | 81 ± 4 | ||
| III, IV | 61 | 18 | 76 ± 6 | 60 | 20 | 69 ± 6 | ||
| IPS | .002 | .003 | ||||||
| 2 or below | 104 | 17 | 83 ± 3 | 103 | 24 | 82 ± 4 | ||
| More than 2 | 35 | 13 | 67 ± 8 | 35 | 15 | 60 ± 8 | ||
| Bulky disease | .65 | .79 | ||||||
| No | 101 | 24 | 81 ± 4 | 100 | 30 | 76 ± 4 | ||
| Yes | 37 | 7 | 86 ± 6 | 37 | 10 | 74 ± 8 | ||
| HGAL | .01 | .05 | ||||||
| Negative | 37 | 13 | 70 ± 8 | 37 | 15 | 70 ± 8 | ||
| Positive | 108 | 18 | 87 ± 3 | 107 | 25 | 79 ± 4 | ||
| B symptoms* | .48 | .14 | ||||||
| No | 73 | 12 | 87 ± 4 | 72 | 16 | 85 ± 4 | ||
| Yes | 46 | 10 | 84 ± 6 | 46 | 15 | 69 ± 7 | ||
| No. of sites* | .79 | .25 | ||||||
| 1-3 | 72 | 13 | 87 ± 4 | 72 | 17 | 83 ± 4 | ||
| More than 3 | 44 | 9 | 82 ± 6 | 43 | 13 | 72 ± 7 | ||
Restricted to patients with stage I or II disease.